NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
Surrozen, Inc. SRZN
6 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
USD 3.5M
Revenue, FY2025 · full 6-year series below
Revenue $M
Net income $M
FY2025 · Revenue 3.5 · Net income -242.0
Compound annual growth
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−6961 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -1210.6% · Net -6960.8%
ROE
FY2024 · ROE -767.9%
The 6-year record
6 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.1 | −0.0 |
| EBITDA $B | · | · | · | · | · | · |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net income $B | −0.2 | −0.1 | −0.0 | −0.0 | −0.1 | −0.0 |
| Free cash flow $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.1 | −0.0 |
| EPS, diluted $ | −32.37 | −21.67 | −21.33 | −15.56 | −2.21 | · |
| Dividend / sh $ | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · |
| ROE % | · | −767.9 | −75.6 | −38.8 | −69.6 | −69.2 |
| Shares out B | 0.01 | 0.00 | 0.00 | 0.00 | 0.04 | 0.02 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 23 reconciliationsAUDITED
Reconciled in 6 of 19 fiscal years. 53 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2020